Compare TSBK & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | CABA |
|---|---|---|
| Founded | 1915 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.0M | 319.6M |
| IPO Year | 1997 | 2019 |
| Metric | TSBK | CABA |
|---|---|---|
| Price | $41.00 | $3.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 18.2K | ★ 4.5M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 21.93 | 10.26 |
| EPS | ★ 1.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.30 | $1.26 |
| 52 Week High | $43.55 | $4.23 |
| Indicator | TSBK | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 55.84 |
| Support Level | $39.81 | $2.11 |
| Resistance Level | $42.40 | $4.23 |
| Average True Range (ATR) | 0.99 | 0.31 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 53.16 | 47.24 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.